A Case of Orofacial Granulomatosis Treated With Intravenous Rituximab

Orofacial granulomatosis (OFG) encompasses a range of conditions marked by granuloma formation in the oral and perioral tissues. We report a 32-year-old female with asymptomatic swelling of the lower lip, buccal mucosa, and lower face, accompanied by difficulty in swallowing over a period of one year. A biopsy indicated OFG. The patient had an inadequate response to a combination of oral prednisolone, azathioprine, and hydroxychloroquine (HCQ). She was treated with three doses of injection rituximab resulting in a 50% reduction in swelling after six months. This case report aims to highlight the challenges of treating OFG, recommending rituximab as a promising therapeutic option, particularly when conventional treatments fail. Further research into biologics for this condition is warranted.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-03-06
DOI
https://doi.org/10.7759/cureus.80123
Primary Topic
Autoimmune and Inflammatory Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Case of Orofacial Granulomatosis Treated With Intravenous Rituximab

S. Selvaraj, Anuradha Priyadarshini, Adikrishnan Swaminathan, Krishnakanth Muralidhar et al.
Cureus
Autoimmune and Inflammatory Disorders
article

A Case of Orofacial Granulomatosis Treated With Intravenous Rituximab

S. Selvaraj, Anuradha Priyadarshini, Adikrishnan Swaminathan, Krishnakanth Muralidhar, Leena Dennis Joseph
article en

Abstract

Orofacial granulomatosis (OFG) encompasses a range of conditions marked by granuloma formation in the oral and perioral tissues. We report a 32-year-old female with asymptomatic swelling of the lower lip, buccal mucosa, and lower face, accompanied by difficulty in swallowing over a period of one year. A biopsy indicated OFG. The patient had an inadequate response to a combination of oral prednisolone, azathioprine, and hydroxychloroquine (HCQ). She was treated with three doses of injection rituximab resulting in a 50% reduction in swelling after six months. This case report aims to highlight the challenges of treating OFG, recommending rituximab as a promising therapeutic option, particularly when conventional treatments fail. Further research into biologics for this condition is warranted.

CureusVol. 17(3)
Sri Ramachandra Institute of Higher Education and Research (IN)
Good health and well-being
Openalex Percentile: Top 94%
Autoimmune and Inflammatory Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.